Status message

Not the entire site translated, but only to "Journal"

Contemporary Problems of Clinical Studies of New Anxiolytics and Antidepressants

T.S. Syunyakov, G.G. Neznamov 
FSBI “Zakusov Institute of Pharmacology”, Moscow, Russia

Abstract
Background: Results and quality of clinical trials are crucial for the clinical practice since these two parameters are reviewed in clinical guidelines. Though there are many identified flaws of the clinical trials of new antidepressants and anxiolytics were strongly criticized. This review aimed to summarize literature from past two decades on methodic and methodological issues of clinical trial of new agents for the treatment of depressive and anxiety disorders.
Results: Clinical trials of antidepressants and anxiolytics inherit common trials problems, but also have some specific issues. Modern procedures and requirements to clinical research of new drugs perform formal tasks for the ultimate goal of official registration of the drug but are not fully acceptable for psychiatry at this stage. Some features of mental disorders classification, lack of understanding of the underlying mechanisms, limitations of psychometric methods, under-controlled placebo effect and many other problems on the part of organizers, performers and subjects of clinical trials can lead to biases in the results. A number of other problems, including ignoring the evaluation of the specific dimensions of the clinical and pharmacological action of the drug, limit the generalizability of the study results.
Conclusions: the emergence of more effective solutions to these problems will increase the adequacy of various aspects of the studies, beginning with the formation of the study hypothesis, selection of efficacy endpoints, study population, and may yield results that could be applied not only to a formalized assessment of the drug efficacy, but also a real-world personalized / stratified prognosis of effectiveness in real clinical settings
Contact: Syunyakov Timur, Sjunja@bk.ru, https://orcid.org/0000-0002-4334-1601
Citation: Syunyakov T.S., Neznamov G.G. Contemporary Problems of Clinical Studies of New Anxiolytics and Antidepressants // Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. – 2020. – No. 4. – P. 2–12. – DOI: 10.21265/PSYPH.2020.67.78.001 [in Russian] Conflict of interest: the authors declare no conflict of interest

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1. Shmukler A.B. Dokazatel'nye issledovaniya v psikhiatrii: analiz prakticheskoi znachimosti // Psikhiatriya i psikhofarmakoterapiya imeni P.B. Gannushkina. ‒ 2012. – № 5. ‒ S. 4–13.
2. Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok, 1996. ‒ 288 s. 
3. Zorin N.V. Vvedenie v dokazatel'nuyu meditsinu. Ch. I // Esteticheskaya meditsina. ‒ 2009. ‒ T. 8, № 2. ‒ S. 155–163.
4. Zorin N. V. Vvedenie v dokazatel'nuyu meditsinu. Ch. III: Prakticheskoe ispol'zovanie dokazatel'nykh dannykh // Esteticheskaya meditsina. ‒ 2009. ‒ T. 7, № 4. ‒ S. 377–383.
5. Mosolov S.N., Kalinin V.V. Metodologiya klinicheskikh ispytanii psikhotropnykh sredstv: posobie dlya vrachei. – M.: Moskovskii nauchno-issledovatel'skii institut psikhiatrii, 2001. ‒ 41 s. 
6. Mora M.S., Nestoriuc Y., Rief W. Lessons learned from placebo groups in antidepressant trials // Philosophical Transactions of the Royal Society B: Biological Sciences. ‒ 2011. ‒ Vol. 366, No. 1572. ‒ P. 1879–1888. – DOI: 10.1098/rstb.2010.0394
7. Heres S., Davis J., Maino K. et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics // The American Journal of Psychiatry. ‒ 2006. ‒ Vol. 163, No. 2. ‒ P. 185–194. – DOI: 10.1176/appi.ajp.163.2.185
8. Dainesi S.M., Elkis H. Current clinical research environment. Focus on Psychiatry // Revista Brasileira de Psiquiatria. ‒ 2007. ‒ Vol. 29, No. 3. ‒ P. 283–290.
9. Marks D.M., Thanaseelan J., Pae C.U. Innovations in clinical research design and conduct in psychiatry: Shifting to pragmatic approaches // Psychiatry Investigation. ‒ 2009. ‒ Vol. 6, No. 1. ‒ P. 1–6. – DOI: 10.4306/pi.2009.6.1.1
10. Wang S.M., Han C., Lee S.J. et al. Efficacy of antidepressants: bias in randomized clinical trials and related issues // Expert Review of Clinical Pharmacology. ‒ 2018. ‒ Vol. 11, No. 1. ‒ P. 15–25. – DOI: 10.1080/17512433.2017.1377070
11. Hyman S.E. Psychiatric drug development: diagnosing a crisis // Cerebrum: The Dana Forum on Brain Science. ‒ 2013, April. ‒ P. 5.
12. Hwang T.J., Carpenter D., Lauffenburger J.C. et al. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results // JAMA Internal Medicine. ‒ 2016. ‒ Vol. 176, No. 12. ‒ P. 1826–1826. – DOI: 10.1001/jamainternmed.2016.6008
13. Fogel D.B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review // Contemporary Clinical Trials Communications. ‒ 2018. ‒ Vol. 11, May. ‒ P. 156–164. – DOI: 10.1016/j.conctc.2018.08.001
14. Ioannidis J.P.A. Why most published research findings are false // Getting to Good: Research Integrity in the Biomedical Sciences. ‒ 2018. ‒ Vol. 2, No. 8. ‒ P. 2–8. – DOI: 10.1371/journal.pmed.0020124
15. Tohen M., Bowden C.L., Nierenberg A. A. et al. Clinical Trial Design Challenges in Mood Disorders. – Academic Press, 2015. ‒ 192 p. 
16. Hrobjartsson A., Thomsen A.S.S., Emanuelsson F. et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors // BMJ. ‒ 2012. ‒ Vol. 344, No. feb27 2. ‒ P. e1119–e1119. – DOI: 10.1136/bmj.e1119
17. Dwan K., Altman D.G., Clarke M. et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials // PLoS Med. ‒ 2014. ‒ Vol. 11. – DOI: 10.1371/journal.pmed.1001666
18. Enck P., Klosterhalfen S., Weimer K. et al. The placebo response in clinical trials: More questions than answers // Philosophical Transactions of the Royal Society B: Biological Sciences. ‒ 2011. ‒ Vol. 366, No. 1572. ‒ P. 1889–1895. – DOI: 10.1098/rstb.2010.0384
19. Hart B., Lundh A., Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses // BMJ. ‒ 2012. ‒ Vol. 344. –  DOI: 10.1136/bmj.d7202
20. Lieb K., Osten-Sacken J.V.D., Stoffers-Winterling J. et al. Conflicts of interest and spin in reviews of psychological therapies: a systematic review // BMJ Open. ‒ 2016. ‒ Vol. 6, No. 4. ‒ P. e010606–e010606. – DOI: 10.1136/bmjopen-2015-010606
21. Taylor D. Prescribing according to diagnosis: how psychiatry is different // World Psychiatry. ‒ 2016. ‒ Vol. 15, No. 3. ‒ P. 224–225. – DOI: 10.1002/wps.20343
22. McGorry P., Keshavan M., Goldstone S. et al. Biomarkers and clinical staging in psychiatry // World Psychiatry. ‒ 2014. ‒ Vol. 13, No. 3. ‒ P. 211–223. –  DOI: 10.1002/wps.20144
23. Brainstorm C., Anttila V., Bulik-Sullivan B. et al. Analysis of shared heritability in common disorders of the brain // Science. ‒ 2018. ‒ Vol. 360, No. 6395. – DOI: 10.1126/science.aap8757
24. Pettersson E., Lichtenstein P., Larsson H. et al. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls // Psychol Med. ‒ 2019. ‒ Vol. 49, No. 7. ‒ P. 1166–1173. – DOI: 10.1017/S0033291718002039
25. Xia C.H., Ma Z., Ciric R. et al. Linked dimensions of psychopathology and connectivity in functional brain networks // Nat Commun. ‒ 2018. ‒ Vol. 9, No. 1. ‒ P. 3003. – DOI: 10.1038/s41467-018-05317-y
26. Borsini F., Podhorna J., Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? // Psychopharmacology (Berl.). ‒ 2002. ‒ Vol. 163, No. 2. ‒ P. 121–141.
27. Anderzhanova E., Kirmeier T., Wotjak C.T. Animal models in psychiatric research: The RDoC system as a new framework for endophenotype-oriented translational neuroscience // Neurobiology of Stress. ‒ 2017. ‒ Vol. 7. ‒ P. 47–56. – DOI: 10.1016/j.ynstr.2017.03.003
28. Grigorova O.V., Akhapkin R.V., Aleksandrovskii Yu.A. Sovremennye predstavleniya o patogeneticheskoi terapii trevozhnykh rasstroistv // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. ‒ 2019. ‒ T. 119, № 10. ‒ S. 111–120. – DOI: 10.17116/jnevro2019119101111
29. Syunyakov T.S., Syunyakov S.A., Dorofeeva O.A. Mekhanizmy anksiogeneza i terapiya trevogi // Psikhiatriya i psikhofarmakoterapiya. ‒ 2011. – № 6. ‒ S. 9–15.
30. Mosolov S.N. Sovremennye biologicheskie gipotezy rekurrentnoi depressii (obzor) // Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova. ‒ 2012. ‒ T. 112, № 11-2. ‒ S. 29–40.
31. Karatsoreos I.N., McEwen B.S. Psychobiological allostasis: resistance, resilience and vulnerability // Trends Cogn Sci. ‒ 2011. ‒ Vol. 15, No. 12. ‒ P. 576–584. – DOI: 10.1016/j.tics.2011.10.005
32. Grande I., Berk M., Birmaher B. et al. Bipolar disorder // Lancet. ‒ 2016. ‒ Vol. 387, No. 10027. ‒ P. 1561–1572. – DOI: 10.1016/S0140-6736(15)00241-X
33. Bratsos S., Saleh S.N. Clinical Efficacy of Ketamine for Treatment-resistant Depression // Cureus. ‒ 2019. ‒ Vol. 11, No. 7. ‒ P. e5189. – DOI: 10.7759/cureus.5189
34. Bolin B.L., Alcorn J.L., Reynolds A.R. et al. Human drug discrimination: A primer and methodological review // Experimental and Clinical Psychopharmacology. ‒ 2016. ‒ Vol. 24, No. 4. ‒ P. 214–228. – DOI: 10.1037/pha0000077
35. Rekomendatsiya Kollegii EEK ot 17 iyulya 2018 g. № 11 «O Rukovodstve po obshchim voprosam klinicheskikh issledovanii». – URL: https://docs.eaeunion.org/docs/ru-ru/01418320/clcr_20072018_11/ (data obrashcheniya 03.09.2019).
36. Woolfolk L.R. Clinical Trials in Psychiatry and Clinical Psychology: Science or Product Testing? // Acta Psychopathologica. ‒ 2015. ‒ Vol. 01, No. 02. ‒ P. 12. – DOI: 10.4172/2469-6676.100012
37. Rothwell P.M. External validity of randomised controlled trials: “to whom do the results of this trial apply?” // Lancet. ‒ 2005. ‒ Vol. 365, No. 9453. ‒ P. 82–93. – DOI: 10.1016/S0140-6736(04)17670-8
38. Mosolov S.N., Kostyukova E.G. Aktual'nye voprosy farmakoterapii depressii // Novye dostizheniya v terapii psikhicheskikh zabolevanii / pod red. S.N. Mosolova. – M.: OOO «BINOM. Laboratoriya znanii», 2002. – S. 211–231.
39. Cipriani A., Furukawa T.A., Salanti G. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis // Lancet (London, England). ‒ 2018. ‒ Vol. 391, No. 10128. ‒ P. 1357–1366. – DOI: 10.1016/S0140-6736(17)32802-7
40. Leucht S., Cipriani A., Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis // Lancet. ‒ 2013. ‒ Vol. 382, No. 9896. ‒ P. 951-62. – DOI: 10.1016/S0140-6736(13)60733-3
41. NICE approves atypical antipsychotics as first-line treatment in schizophrenia [Intenet] // The Pharmaceutical Journal. – 2002 – Vol. 268, No. 7201. – P. 793–795. URL: https://www.pharmaceutical-journal.com/pj-online-news-nice-approves-atyp...
42. Kuipers E., Yesufu-Udechuku A., Taylor C. et al. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance // BMJ (Clinical research ed.). ‒ 2014. ‒ Vol. 348, No. feb12 1. ‒ P. g1173–g1173. – DOI: 10.1136/bmj.g1173
43. Stahl S. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. – Cambridge: Cambridge University Press, 2013. – 662 p.
44. Neznanov N.G., Martynikhin I.A., Mosolov S.N. Diagnostika i terapiya trevozhnykh rasstroistv v Rossiiskoi Federatsii: rezul'taty oprosa vrachei-psikhiatrov // Sovremennaya terapiya psikhicheskikh rasstroistv. ‒ 2017. – № 2. ‒ S. 2–13. – DOI: 10.21265/PSYPH.2017.41.6437
45. Carlisle B., Kimmelman J., Ramsay T. et al. Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials // Clinical Trials. ‒ 2015. ‒ Vol. 12, No. 1. ‒ P. 77–83. – DOI: 10.1177/1740774514558307
46. de Mathis M.A., Diniz J.B., Hounie A.G. et al. Trajectory in obsessive-compulsive disorder comorbidities // Eur Neuropsychopharmacol. ‒ 2013. ‒ Vol. 23, No. 7. ‒ P. 594–601. – DOI: 10.1016/j.euroneuro.2012.08.006.
47. Smolik P. Validity of nosological classification // Dialogues in clinical neuroscience. ‒ 1999. ‒ Vol. 1, No. 3. ‒ P. 185–190.
48. March J.S., Silva S.G., Compton S. et al. The case for practical clinical trials in psychiatry // American Journal of Psychiatry. ‒ 2005. ‒ Vol. 162, No. 5. ‒ P. 836–846. – DOI: 10.1176/appi.ajp.162.5.836
49. Jablensky A. Psychiatric classifications: validity and utility // World Psychiatry. ‒ 2016. ‒ Vol. 15, No. 1. ‒ P. 26–31. – DOI: 10.1002/wps.20284
50. Regier D.A., Narrow W.E., Clarke D.E. et al. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses // Am J Psychiatry. ‒ 2013. ‒ Vol. 170, No. 1. ‒ P. 59–70. – DOI: 10.1176/appi.ajp.2012.12070999
51. Khan A., Faucett J., Brown W.A. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews // Journal of Psychiatric Research. ‒ 2014. ‒ Vol. 51, No. 1. ‒ P. 88-92. – DOI: 10.1016/j.jpsychires.2014.01.005
52. Sheehan D.V., Lecrubier Y., Sheehan K.H. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 // The Journal of clinical psychiatry. ‒ 1998. ‒ Vol. 59, Suppl. 2. ‒ P. 22–33; quiz 34–57.
53. Mosolov S.N., Kostyukova E.G., Avedisova A.S., Akhapkin R.V. Nekotorye metodicheskie problemy klinicheskogo izucheniya antidepressantov (na primere rossiiskogo mul'titsentrovogo dvoinogo-slepogo platsebo-kontrolirumaego issledovaniya reboksetina) // Novye dostizheniya v terapii psikhicheskikh zabolevanii / pod red. S.N. Mosolova. – M.: OOO «BINOM. Laboratoriya znanii», 2002. – S. 245–265.
54. Hobart J.C., Cano S.J., Zajicek J.P. et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations // The Lancet Neurology. ‒ 2007. ‒ Vol. 6, No. 12. ‒ P. 1094–1105. – DOI: 10.1016/S1474-4422(07)70290-9
55. Maj M. The crisis of confidence in the DSM paradigm and the future of psychiatric diagnosis // Die Psychiatrie. ‒ 2015. ‒ Vol. 12, No. 02. ‒ P. 67–68. – DOI: 10.1055/s-0038-1669887
56. Avrutskii G.Ya., Zaitsev S.G. Klinicheskie ispytaniya psikhotropnykh sredstv. Farmakologiya. Khimioterapevticheskie sredstva. T. 9: Doklinicheskoe i klinicheskoe ispytanie lekarstvennykh sredstv (Itogi nauki i tekhniki. VINITI AN SSSR). – M., 1977. – S. 49–78. 
57. Liberman R. A criticism of drug therapy in psychiatry // Archives of General Psychiatry. ‒ 1961. ‒ Vol. 4, No. 2. ‒ P. 131–136. – DOI: 10.1001/archpsyc.1961.01710080027005
58. Andreasen N.C. DSM and the death of phenomenology in america: an example of unintended consequences // Schizophrenia Bulletin. ‒ 2007. ‒ Vol. 33, No. 1. ‒ P. 108–112. – DOI: 10.1093/schbul/sbl054
59. Furukawa T.A. Assessment of mood: guides for clinicians // J Psychosom Res. ‒ 2010. ‒ Vol. 68, No. 6. ‒ P. 581–589. – DOI: 10.1016/j.jpsychores.2009.05.003
60. Bech P. Clinical Psychometrics. ‒ Chichester, West Sussex, UK: John Wiley & Sons, Ltd, 2012. 
61. Joyce D.W., Tracy D.K., Shergill S.S. Are we failing clinical trials? A case for strong aggregate outcomes // Psychological Medicine. ‒ 2018. ‒ Vol. 48, No. 2. ‒ P. 177–186. – DOI: 10.1017/S0033291717001726
62. Aleksandrovskii Yu.A., Rudenko G.M., Neznamov G.G. i dr. Unifitsirovannaya sistema otsenki kliniko-farmakologicheskogo deistviya psikhotropnykh preparatov u bol'nykh s pogranichnymi nervno-psikhicheskimi rasstroistvami: metod. rekomendatsii. ‒ M.: Ministerstvo zdravokhraneniya SSSR, 1984. ‒ 69 s. 
63. Seredenin S.B., Voronina T.A., Neznamov G.G., Zherdev V.P. Fenazepam. 25 let v meditsinskoi praktike. – M.: Nauka, 2007. – 381 s. 
64. Lydiard R.B., Rickels K., Herman B. et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder // Int J Neuropsychopharmacol. ‒ 2010. ‒ Vol. 13, No. 2. ‒ P. 229–241. – DOI: 10.1017/S1461145709990460
65. Fournier J.C., DeRubeis R.J., Hollon S.D. et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis // JAMA. ‒ 2010. ‒ Vol. 303, No. 1. ‒ P. 47–53. – DOI: 10.1001/jama.2009.1943
66. Kirsch I., Deacon B.J., Huedo-Medina T B. et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration // PLoS medicine. ‒ 2008. ‒ Vol. 5, No. 2. ‒ P. e45-e45. – DOI: 10.1371/journal.pmed.0050045
67. Kirsch I., Sapirstein G. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication // Prevention & Treatment. ‒ 1998. ‒ Vol. 1, No. 2. – DOI: 10.1037/1522-3736.1.1.12a
68. Turner E.H., Matthews A.M., Linardatos E. et al. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy // New England Journal of Medicine. ‒ 2008. ‒ Vol. 358, No. 3. ‒ P. 252–260. – DOI: 10.1056/NEJMsa065779
69. Walsh B.T., Seidman S.N., Sysko R. et al. Placebo Response in Studies of Major Depression // JAMA. ‒ 2002. ‒ Vol. 287, No. 14. ‒ P. 1840–1840. – DOI: 10.1001/jama.287.14.1840
70. Montgomery S.A. Rapid onset of action of venlafaxine // International Clinical Psychopharmacology. ‒ 1995. ‒ Vol. 10. ‒ P. 21–28. – DOI: 10.1097/00004850-199503002-00005
71. Newport D.J., Carpenter L.L., McDonald W.M. et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression // Am J Psychiatry. ‒ 2015. ‒ Vol. 172, No. 10. ‒ P. 950–966. – DOI: 10.1176/appi.ajp.2015.15040465
72. Ragguett R.M., Rong C., Kratiuk K. et al. Rapastinel – an investigational NMDA-R modulator for major depressive disorder: evidence to date // Expert Opinion on Investigational Drugs. ‒ 2019. ‒ Vol. 28, No. 2. ‒ P. 113–119. – DOI: 10.1080/13543784.2019.1559295
73. Shiovitz T.M., Zarrow M.E., Shiovitz A.M. et al. Failure rate and “Professional subjects” in clinical trials of major depressive disorder // Journal of Clinical Psychiatry. ‒ 2011. ‒ Vol. 72, No. 9. ‒ P. 1284–1284. – DOI: 10.4088/JCP.11lr07229
74. Khan A., Kolts R.L., Thase M.E. et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials // American Journal of Psychiatry. ‒ 2004. ‒ Vol. 161, No. 11. ‒ P. 2045–2049. – DOI: 10.1176/appi.ajp.161.11.2045
75. Rief W., Nestoriuc Y., Weiss S. et al. Meta-analysis of the placebo response in antidepressant trials // Journal of Affective Disorders. ‒ 2009. ‒ Vol. 118, No. 1-3. ‒ P. 1–8. – DOI: 10.1016/j.jad.2009.01.029
76. Schedlowski M., Enck P., Rief W. et al. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: Implications for clinical trials and clinical practice // Pharmacological Reviews. ‒ 2015. ‒ Vol. 67, No. 3. ‒ P. 697–730. – DOI: 10.1124/pr.114.009423
77. Andrews G. Efficacy, Effectiveness and Efficiency in Mental Health Service Delivery // Australian & New Zealand Journal of Psychiatry. ‒ 1999. ‒ Vol. 33, No. 3. ‒ P. 316–322. – DOI: 10.1046/j.1440-1614.1999.00581.x
78. Purgato M., Barbui C., Stroup S. et al. Pragmatic design in randomized controlled trials // Psychological Medicine. ‒ 2015. ‒ Vol. 45, No. 2. ‒ P. 225–230. – DOI: 10.1017/S0033291714001275
79. Thorpe K.E., Zwarenstein M., Oxman A.D. et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers // Canadian Medical Association Journal. ‒ 2009. ‒ Vol. 180, No. 10. ‒ P. E47–E57. – DOI: 10.1503/cmaj.090523
80. Korte S.M., Prins J., Krajnc A.M. et al. The many different faces of major depression: it is time for personalized medicine // Eur J Pharmacol. ‒ 2015. ‒ Vol. 753. ‒ P. 88–104. – DOI: 10.1016/j.ejphar.2014.11.045.
81. Basu S. Personalized versus evidence-based medicine with PET-based imaging // Nat Rev Clin Oncol. ‒ 2010. ‒ Vol. 7, No. 11. ‒ P. 665–668. – DOI: 10.1038/nrclinonc.2010.121
82. Lenze E.J., Wetherell J.L. Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late-life anxiety disorders // Int J Geriatr Psychiatry. ‒ 2009. ‒ Vol. 24, No. 1. ‒ P. 1–14. – DOI: 10.1002/gps.2074
83. Hyde L.W., Bogdan R., Hariri A.R. Understanding risk for psychopathology through imaging gene-environment interactions // Trends Cogn Sci. ‒ 2011. ‒ Vol. 15, No. 9. ‒ P. 417–427. – DOI: 10.1016/j.tics.2011.07.001
84. Rutledge R.B., Chekroud A.M., Huys Q.J. Machine learning and big data in psychiatry: toward clinical applications // Curr Opin Neurobiol. ‒ 2019. ‒ Vol. 55. ‒ P. 152–159. – DOI: 10.1016/j.conb.2019.02.006